Eisai launches LEQEMBI for early Alzheimer’s disease treatment in India
Eisai has launched LEQEMBI (lecanemab) in India after receiving CDSCO approval, introducing the country's first disease-modifying therapy for early Alzheimer's disease. The treatment is indicated for patients with mild cognitive impairment and mild dementia and aims to slow disease progression.
Hyderabad: Eisai, the noted Japanese pharmaceutical company headquartered, announced the launch of Leqembi (lecanemab) for treatment of early Alzheimer’s disease, following marketing authorisation from Central Drugs Standard Control Organization (CDSCO).
In India, LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer’s disease, marking the introduction of this first-of-its-kind Disease-Modifying Therapy (DMT) in the country’s Alzheimer’s disease treatment landscape, the pharma company said in a statement on Monday.
LEQEMBI has received approvals in several developed markets including the United States, Japan and across Europe, as well as select developing countries. Further, there is emerging real-world experience indicating the potential value of LEQEMBI in slowing disease progression and improving patient outcomes, Eisai said.
LEQEMBI (lecanemab) is a humanised monoclonal antibody that selectively targets aggregated amyloid-beta, enabling its clearance while reducing further deposition. It is approved for use in early-stage Alzheimer’s disease, including MCI and mild dementia.
“What is promising about LEQEMBI (lecanemab) is its ability to intervene early in the disease process,” said Ritesh Jain, Head of Commercial Operations, Eisai India.
Access and awareness remain critical barriers in Alzheimer’s disease care in India. Our support programmes are aimed at helping eligible patients initiate and continue therapy, in line with our human health care philosophy,” Takuya Kijima, Managing Director, Eisai India, said.
